American Regent v. Aspiro Pharma: Selenious Acid Patent Case Consolidated in 21 Days
American Regent, Inc. filed suit against Aspiro Pharma Ltd. on December 13, 2024, asserting patent US12150957B2 over selenious acid pharmaceutical products. Within 21 days the case was consolidated into a 13-defendant omnibus action — In re Selenious Acid Litigation — before the New Jersey District Court.
One of 12 parallel ANDA suits folded into a coordinated selenious acid battle
On December 13, 2024, American Regent, Inc. (ARI) filed Civil Action No. 2:24-cv-11109 against Aspiro Pharma Ltd. in the District of New Jersey, asserting infringement of US12150957B2 relating to selenious acid products. The filing was one of twelve near-simultaneous actions ARI initiated on the same date against generic pharmaceutical manufacturers, a pattern consistent with a Hatch-Waxman paragraph IV ANDA certification challenge triggering the statutory 45-day suit window.
The case closed on January 3, 2025 — just 21 days after filing — when the court consolidated it into the already-pending omnibus proceeding, In re Selenious Acid Litigation (Civil Action No. 2:24-cv-7791). All future filings, including those involving Aspiro Pharma, are now maintained under the lead case caption. The consolidation was stipulated by all parties, suggesting coordinated agreement among counsel rather than a contested procedural motion.
The 21-day resolution timeline reflects administrative consolidation rather than any substantive disposition on the merits; the underlying infringement claims remain live in the lead case. The breadth of the defendant roster — spanning Accord Healthcare, Cipla, Dr. Reddy’s, Hikma, Sun Pharma, Zydus, and others — suggests the selenious acid patent faces widespread generic challenge, which typically signals significant commercial stakes for ARI’s branded product franchise. Merits rulings, claim construction, and any potential 30-month stay determination will emerge from the consolidated docket.
Filing to Case Consolidated in 21 days
21 days to consolidation — significantly faster than the typical ANDA multi-defendant consolidation timeline
Case consolidated: what the transfer to In re Selenious Acid Litigation means
Consolidation merges dockets, not claims
A consolidation order under Fed. R. Civ. P. 42(a) combines cases sharing common questions of law or fact into a single proceeding. This case was not dismissed — the infringement claims against Aspiro Pharma remain active and will be adjudicated in lead case No. 2:24-cv-7791. All filings, discovery, and scheduling orders will now be issued under the consolidated caption.
Claims survive — venue unchangedARI gains procedural efficiency across 13 defendants
Consolidation benefits American Regent by allowing unified claim construction, coordinated discovery, and a single trial schedule against all generic challengers simultaneously. This reduces litigation costs and prevents inconsistent rulings across parallel dockets. ARI retains all infringement claims against Aspiro Pharma and can pursue them alongside actions against Accord, Cipla, Dr. Reddy’s, Hikma, Sun Pharma, and others.
ARI retains all claimsAspiro Pharma enters a multi-defendant litigation arena
Aspiro Pharma now litigates as part of a larger defendant group, which can create both advantages and complexities. Shared discovery and common claim construction positions may reduce individual costs, but defendants with divergent ANDA formulations or invalidity theories may face strategic tension. Aspiro’s individual ANDA product scope and any unique defenses will still need to be addressed within the consolidated framework.
Litigation continues in lead caseBroad generic challenge signals high commercial value of selenious acid IP
Twelve simultaneous ANDA filers against a single patent is consistent with a high-value, off-patent brand product facing a wave of generic entry. The consolidated proceeding will set a single precedent on validity and infringement for all challengers. A ruling favoring ARI would block multiple generic entrants simultaneously; a ruling favoring defendants could open the market to immediate multi-source competition.
High-stakes multi-generic entry riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical manufacturer and IV drug maker — holder of US12150957B2Search in Eureka ↗ |
| Defendant | ASPIRO PHARMA LTD. | Company | Aspiro Pharma Ltd. — generic pharmaceutical manufacturer and ANDA applicantSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated consolidation order does not constitute a merits ruling on infringement or validity. The language reflects a purely procedural agreement: all parties consented to merge this action into In re Selenious Acid Litigation. For Aspiro Pharma, this means no admission of infringement and no dismissal of defenses. For American Regent, all asserted claims under US12150957B2 remain live. The commercial and legal outcome will turn entirely on proceedings in the lead case, No. 2:24-cv-7791.
US12150957B2 — Selenious Acid Injectable Pharmaceutical Formulations
US12150957B2, filed under application number US18/672876, covers selenious acid products in the pharmaceutical injectable space — most likely formulations used in parenteral nutrition or trace element supplementation for hospitalised patients. Selenious acid is a selenium-containing compound administered intravenously when oral intake is not possible. The patent’s grant date and application number suggest a relatively recent prosecution history, and its assertion against 12 simultaneous ANDA filers indicates ARI views it as commercially foundational to its selenious acid product franchise.
The breadth of the generic defendant roster — spanning major international pharmaceutical manufacturers including Cipla, Dr. Reddy’s, Hikma, and Sun Pharma — suggests the market exclusivity conferred by US12150957B2 is commercially significant. For competitors developing injectable selenium formulations or parenteral trace element products, this patent represents a material freedom-to-operate risk. The consolidated litigation will likely produce claim construction rulings that define the enforceable scope, making early monitoring of the lead docket essential for any party in this space.
Should you run an FTO analysis against US12150957B2?
Any company developing, manufacturing, or seeking ANDA approval for selenious acid injectable products or parenteral trace element formulations should treat US12150957B2 as a live FTO concern. The active consolidated litigation demonstrates that American Regent is enforcing this patent aggressively and simultaneously against the industry’s largest generic manufacturers. A positive FTO posture cannot be assumed simply because other ANDAs are pending — each product formulation requires independent analysis.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US12150957B2 against your product specifications, identify prior art relevant to validity challenges, and flag related patents in ARI’s portfolio that may present additional risk. Given the multi-defendant consolidation, Eureka can also surface the litigation history of each co-defendant to inform your competitive intelligence and help you assess whether an IPR petition or inter partes review strategy is viable before the consolidated trial schedule is set.
Run a freedom-to-operate analysis on US12150957B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA patent cases in pharmaceutical formulations
Explore related ANDA infringement actions involving injectable pharmaceutical formulations litigated in the District of New Jersey — the primary venue for Hatch-Waxman disputes.
What this case signals for the pharmaceutical patent IP landscape
Coordinated multi-defendant ANDA litigation over injectable formulations is intensifying. This case illustrates the strategic mechanics.
Simultaneous ANDA filings compress patent holder response windows
ARI filed 12 infringement suits on the same day, consistent with the Hatch-Waxman 45-day window triggered by paragraph IV certifications. Patent holders facing multiple simultaneous ANDA filers should prepare consolidated litigation infrastructure in advance — consolidation is likely and rapid, as this case demonstrates with a 21-day closure.
Consolidation is not resolution — monitor the lead docket actively
Case closure in 21 days can mislead docket-monitoring systems into categorising this matter as resolved. In reality, the infringement action survives in No. 2:24-cv-7791. IP teams tracking this technology area must follow the lead case, not the individual dockets, for substantive developments including claim construction and trial scheduling.
American v ASPIRO — key questions answered
The case was filed on December 13, 2024 and consolidated into In re Selenious Acid Litigation (No. 2:24-cv-7791) on January 3, 2025 — 21 days later. No merits ruling was issued. American Regent’s infringement claims against Aspiro Pharma under US12150957B2 remain active in the lead consolidated case before the New Jersey District Court.
American Regent asserts US12150957B2 (application number US18/672876), which covers selenious acid pharmaceutical products — most likely injectable formulations used in parenteral nutrition. The same patent is asserted against all 12 co-defendants in the consolidated proceeding.
Consolidation under Fed. R. Civ. P. 42(a) is a procedural mechanism — it does not dismiss any claims. American Regent’s infringement allegations against Aspiro Pharma survive and will be litigated in the lead case, No. 2:24-cv-7791. All future filings, discovery, and rulings will be issued under the consolidated caption.
Filing simultaneous suits on the same date is consistent with the Hatch-Waxman Act’s framework, under which a patent holder has 45 days from receiving paragraph IV ANDA certification notices to file suit and trigger a 30-month stay of FDA approval. Multiple ANDAs filed around the same time would produce concurrent notice letters, resulting in simultaneous suits.
The consolidated proceeding includes: Accord Healthcare, Aspiro Pharma, Cipla USA and Cipla Limited, Dr. Reddy’s Laboratories (US and India), Gland Pharma, Hikma Pharmaceuticals USA, RK Pharma, Somerset Therapeutics/Somerset Pharma/Odin Pharmaceuticals, Sun Pharmaceutical Industries (US and India), Xiromed LLC and Xiromed Pharma España, and Zydus Pharmaceuticals (USA). All actions are now consolidated under Civil Action No. 2:24-cv-7791.
PatSnap Eureka searches patents and litigation data to answer instantly.